FaCT Trial (Facilitated Cascade Testing Trial)

Running, not enrolling · Not applicable

Conditions studied: BRCA1 Mutation, BRCA2 Mutation

In brief

The purpose of this study is to assess an intervention that incorporates engagement strategies with a medical team navigator, an educational video and accessible genetic testing services to maximize the genetic testing and education of at-risk relatives. In this study, first degree relatives who agree to participate will either receive this intervention or standard of care. The investigators do not know if the facilitated interventional method will be more effective than the standard of care method. This research is being done because identification of patients with inherited gynecologic/breast cancer syndromes is critical to enable delivery of tailored cancer treatment and cancer prevention to both the patients and their at-risk relatives. Cascade genetic testing, defined as extending genetic testing to the family members of affected patients, results in a more precise risk assessment and initiation of appropriate cancer screening and prevention strategies. Therefore, this trial will compare the efficacy of a multicomponent facilitated intervention for first degree relatives vs. standard of care in terms of the overall proportion of first degree relatives who complete genetic testing by 6 months (primary outcome).

Key facts

Study ID

NCT04613440

Run by

Weill Medical College of Cornell University

People needed

524

Starts

2021-07-21

Expected to finish

2026-09-18

Last updated by the study team

2026-06-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18 years of age or older as documented in the medical record
• Speaks and reads English or Spanish as reported by the patient
• Patients who are currently receiving diagnostic, treatment, or follow-up care at New York Presbyterian/ Weill Cornell Medical Center, MD Anderson Cancer Center, Duke University or Columbia University.
• Patients with a newly diagnosed BRCA mutation presenting for consultation OR patients with known BRCA mutations who have been diagnosed with a confirmed deleterious (pathogenic) variant in BRCA1, or BRCA2 within the preceding 12 months as documented in the medical record
• BRCA1/2 mutation that is included on testing panel provided by the clinical genetic testing laboratory
• Patients who have at least one at risk relative who meets criteria for first degree relatives

You may not qualify if…

• Is unwilling or unable to provide informed consent.
• Does not have email access.

Where it is running

• Weill Cornell Medicine — New York, New York, United States
• Duke University — Durham, North Carolina, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.